Our Ingredients

Biolane(Green Lipped Mussel Extract Powder)

Biolane is the original, unique extract from the New Zealand Green-Lipped Mussel

Biolane is the original, unique extract from the New Zealand Green-Lipped Mussel (Perna canaliculus). This extract has been the subject of numerous in vitro and in vivo studies, toxicity and teratogenic studies and clinical trials. It has been marketed around the world for the past 36 years with impressive success in treating both the rheumatoid and osteo forms of arthritic disorders.

While there are other Green –Lipped mussel products now on the market, Biolane is the only product to have been proven by independent, high quality science, to inhibit the degenerative processes that take place in joints with aging. It is the multicomponent and multifunctional properties of Biolane that provide the functions to inhibit inflammatory conditions, inhibit histamine production and inhibit cartilage and joint tissue degeneration.

These functions are due to the unique processing protocols employed in the processing of the extract maintaining the bioactive components in their fully active form.

Biolane Pharmacology

The principal anti-inflammatory activity in Biolane is due to a carbohydrate complex that inhibits the emigration of Macrophages, Neutrophils and T-lymphocytes from the vascular system. Changes in endothelial cell adhesion and permeability allow inflammatory, auto-immune reactions to take place and inhibition of these processes is a mediating mechanism in the pathology of inflammatory diseases.

The second anti-inflammatory activity is due to the effect of the natural content in Biolane of long chain fatty acids on cyclo-oxygenase and also 5-lipoxygenase activities. These cyclo-oxygenase (COX and LOX) compounds are enzymes which the body uses to biosynthesise chemicals called prostaglandins, prostacyclins, thromboxanes and leukotrienes. There are two forms of these COX enzymes. COX-1 is constitutive and a natural component of normal tissue. It performs important functions in our body. The other form COX-II is induced when a disease state, such as arthritis, occurs and it produces pro-inflammatory prostaglandins. The 5-lipoxygenase enzyme creates pro-inflammatory and broncho-constrictive leukotrienes. It is therefore desirable to inhibit the COX-II and Leukotriene enzyme activities. However, it is very important that the inhibition is at a moderate level not a high level. Briefly, the reason is that the COX-1 functions also produce thromboxanes which can cause cardiovascular problems. The COX-II functions (which we need to mediate because they are pro-inflammatory) happen to produce prostacyclins and these mediate the undesirable thromboxanes! These immunological and enzymic functions are critically involved in the pathology of arthritis. And it is important to mediate them but at a moderate level.

In addition to these activities, because it is of marine origin, Biolane has a natural content of mineral salts present at a soluble and easily assimilated level. Some of these minerals such as boron, manganese and copper are anti-inflammatory in their own right.

Incidentally another valuable feature of Biolane is that it has been found to have natural gastroprotective properties. This means that, not only does it not damage the delicate stomach lining, it actually provides a protective function for it. Thus the product is able to relieve the inflammatory symptoms associated with arthritic diseases while protecting the stomach from the damaging effect of some of the pain relieving products.

Biolane has a natural content of glycosaminoglycans which is the name for a group of polysaccharides which includes chondroitin sulphate, dermatan sulphate, hyaluronic acid etc. Glycosaminoglycans are used by the body for the biosynthesis of compounds called proteoglycans. The proteoglycans have a very strong affinity for water molecules in the joints, to which they bind, and form very large, space filling molecules. The function of these large combination molecules is to act as shock absorbers and also lubricants in the joints. There is a possibility that these glycosaminoglycans may also help to rebuild cartilage though this has yet to be proven conclusively.

Matrix Metalloprotease Inhibition

In young people and those not affected by arthritis, the rate of cartilage degeneration in the joints is equalled by that of regeneration (homeostasis). In older people and in arthritic disease states this balance is upset leading to accelerated degeneration of cartilage and tissue and reduced lubrication in the joint. Cytokine induced matrix metalloprotease (MMP) activity is responsible for this breakdown in the integrity of the joint structure which causes pain, lack of mobility and significantly reduced quality of life.

In advanced research studies Biolane has been shown to effectively inhibit matrix metalloprotease (MMP) activity across a range of 14 MMPs. The studies were conducted at an independent specialist laboratory and all factions of the studies were thoroughly validated to international standards.

MMPs are a subclass of endopeptidases, (enzymes responsible for breaking down proteins) and predominantly break down collagen and elastin. These are important components in the joint cartilage and their breakdown, in particular by MMP-1, MMP-3, MMP-8 and MMP-13 results in painful joints with reduced mobility.

The first histogram below gives the cumulative values for the inhibition of MMPs by Biolane versus a control based on the results of repeated experiments.

They indicate that Biolane provided excellent inhibition across the range of MMPs from MMP-1 to MMP 14 with significant inhibition of MMP-1,-3 -8 and-13, the ones directly involved in the degredation of collagen and elastin.

The second histogram gives the values for inhibition of the same range of MMPs by Biolane compared to those for other mussel products subjected to the identical experimental protocol. The other mussel products are competitors to Biolane and embrace mussel powders, other mussel extract powders and mussel lipids including Lyprinol. It can be clearly seen that none of these other mussel products had any significant effect on MMP inhibition.

Summary

Biolane has been shown to have anti-inflammatory, anti-histamine and chondroprotective properties all of which are necessary for a comprehensive treatment for the pathologies involved in rheumatoid and osteo arthritic disorders. A significant added benefit is that Biolane achieves this without the complications created by serious adverse side effects. Although there are other mussel products that may address the inflammatory aspect of arthritic disorders, Biolane is the only product to have been proven, using quality science to international standards, to inhibit the degenerative functions of the matrix metalloproteases. This is possible the most important function of a product used to extend quality of life into old age when the degenerative processes in the body’s joints cause pain and decreased mobility. This feature alone makes Biolane so valuable for everyone over the age of 50 years and especially for athletes and sports men and women whose joints have been subjected to more than average wear and tear.

Dosage

The recommended dosage for Biolane is 1000mg per day preferably taken just before a meal. Once a satisfactory degree of relief from pain and freedom of movement has been achieved the dosage can be reduced to 500mg per day for maintenance.

Contraindications

Biolane does not contraindicate with prescription medications for arthritic disorders and can be taken by all age groups from early childhood through to very old age.

Biolane is not recommended, however, for anyone using

  • Monoamine oxidase inhibitors
  • Warfarin or similar agents for serious cardiovascular conditions
  • Or for: People with gout (they also shouldn’t have wines, cheese or shellfish)
    • Although proven safe for pregnancy in teratogenic studies, it is recommended that Biolane not be used during pregnancy due to the unpredictable hormonal activities that some women experience.

      Results for MMP Inhibition
      Results for MMP Inhibition

      Biolane significantly inhibited a range of MMP enzyme activities in vitro including:

      • MMP 1 or Interstitial Collagenase – cleaves fibrillar collagen, degrades interstitial collagens, types I, II and III.
      • MMP 3 or Stromelysin – extracellular endopeptidase, digests proteoglycan; fibronectin; collagen types III IV IV, and IX, and activates procollagenase.
      • MMP 8 or Collagenase 2 – cleaves triple-helical collagen types I, II, and III.
      • MMP 13 or Collagenase 3 – a secreted MMP that plays a physiological role in the degradation of extracellular matrix found in skeletal tissues.

References
  1. Daum A. The influence of Seatone (RO 49-0282/100), and fractions of Seatone, on the established adjuvant arthritis of the rat. Roche Laboratories, Switzerland, 1976
  2. Gibson RG, Gibson SLM, Conway V, et al. Perna canaliculus in the treatment of arthritis. Practitioner 1980; 224: 955-60
  3. Miller TE, Ormrod D. The anti-inflammatory activity of Perna canaliculus (NZ green-lipped mussel). NZ Med J 1980; 92: 187-93
  4. Rainsford KD, Whitehouse MW. Gastroprotective and anti-inflammatory properties of green lipped mussel (Perna canaliculus) preparation. Arzneim Forsch/Drug Res 1980; 30 (II): 2128-32
  5. Couch RAF, Ormrod DJ, Miller TE, Watkins WB. Anti-inflammatory activity in fractionated extracts of the green-lipped mussel. NZ Med J 1982; 95 (720): 803-6
  6. Miller TE, Ormrod DJ, Findon G. Evaluation of the effect of Seatone administration on cell-mediated immune mechanisms determined using in vitro and in vivo analysis of T lymphocyte function. Private study in the Department of Medicine, University of Auckland, 1984.
  7. Miller TE, Wu H. In vivo evidence for prostaglandin inhibitor activity in New Zealand green-lipped mussel extract. NZ Med J 1984; 97: 355-7
  8. Lambert M, Semark A, Grobler L. The ergogenic properties of Seatone®. Research Report by MRC/UCT Bioenergetics of Exercise Research Unit, UCT Medical School, Sport Science Institute of South Africa, 31st August 1998
  9. Orima H, Fujita M, Omura T, Kirihara N. Clinical effects of the extract of the New Zealand green-lipped mussel on dogs and cats with joint diseases. Report from the Nippon Veterinary and Animal Science University, Japan, 1998
  10. Ankenbauer-Perkins K, Slacek B, Alexander A, et al. Final report on the efficacy of green-lipped mussel extract in the management of degenerative joint disease in dogs. Study no. AHSC-75353. September 1999. Animal Health Sciences Centre, Massey University, Palmerston North, New Zealand. Equine Veterinary Journal ISSN 0425-1644DOI: 10.1111/j.2042-3306.2011.00455.
  11. A randomised, double-blinded, placebo-controlled study on the efficacy of a unique extract of green-lipped mussel (Perna canaliculus) in horses with chronic fetlock lameness attributed to osteoarthritis
  12. Audeval B, Bouchacourt P. Double-blind, placebo-controlled study of the mussel Perna canaliculus (New Zealand green-lipped mussel) in gonarthrosis (arthritis of the knee). La Gazette Medicale 1986; 93 (38): 111-5
  13. Kosuge T, Tsuji K, Ishida H, Yamaguchi T. Isolation of an anti-histaminic substance from green-lipped mussel (Perna canaliculus). Chem Pharm Bull 1986; 34 (11): 4825-8
  14. Knaus UG, Tubar A, Wagner H. Pharmacological properties of glycogens: anti-complementary and anti-inflammatory action of mussel glycogen (Perna canaliculus). Department of Immunology
  15. Imm2, Scripps Clinic and Research Foundation, La Jolla, California, USA. Also Universities of Trieste, Italy and Munich, Germany, 1990
  16. Miller TE, Dodd J, Ormrod DJ, Geddes R. Anti-inflammatory activity of glycogen extracted from Perna canaliculus (NZ green-lipped mussel). Agents Actions 1993; 38 (Special Conference issue): C139-42
  17. J. CAYZER*, D. HEDDERLEY† and S. GRAY‡ A randomised, double-blinded, placebo-controlled study on the efficacy of a unique extract of green-lipped mussel (Perna canaliculus) in horses with chronic fetlock lameness
  18. attributed to osteoarthritis.ev Equine Veterinary Journal ISSN 0425-1644
  19. DOI: 10.1111/j.2042-3306.2011.00455.xj_455 393..398
Raw materials, OEM and PB option at Heimat Co., Japan Ltd
APCGCT: Asia Pacific Consortium of Gene and Cell Therapy